Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1737927/000156459020038957/cgc-10q_20200630.htm
February 2023
February 2023
January 2023
December 2022
November 2022
November 2022
November 2022
October 2022
September 2022
September 2022
April 2020
March 2020
March 2020
March 2020
March 2020
February 2020
February 2020
January 2020
January 2020
January 2020
Exhibit 99.1
CANOPY GROWTH REPORTS FIRST QUARTER FISCAL 2021 FINANCIAL RESULTS
Transformation strategy gains traction
Net Revenue of $110 million increases 22% over Q1 FY20
Net Loss of $128 million; Adjusted EBITDA loss of $92 million narrows versus Q1 FY20
Established leadership position in growing cannabis-infused beverage segment; shipping +1.2mm cans to Canadian provinces since launch
Strengthened foothold in U.S. market with launch of shopcanopy.com
August 10, 2020
SMITHS FALLS, ON — Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NYSE:CGC) today announced its financial results for the first quarter fiscal 2021 ended June 30, 2020. All financial information in this press release is reported in millions of Canadian dollars, unless otherwise indicated.
“We’re proud of our strong first-quarter performance, despite unprecedented volatility and uncertainty in the market and across the globe,” said David Klein, CEO. “We grew our revenue year-over-year and are seeing market share improvement, notably achieving number one market share in cannabis-infused beverages in the Canadian market. We are implementing a renewed corporate strategy with the appointment of a new leadership team which will focus on delivering quality products to our consumers, positioning our business for continued growth. The proposed retooled Acreage announcement refocuses our entry for the evolving U.S. market, where we are seeing increased momentum."
“Following our previously announced restructuring actions, we have substantially reduced our expense and cash burn in this quarter in addition to reducing headcount by over 18% since beginning of this calendar year. Our marketing and R&D investments are being re-allocated to programs with high-return potential in order to drive sales", added Mike Lee, CFO. “Our gross margins in the quarter came in below our expectations due to under-utilization of our large-scale infrastructure. We've already proven we can deliver 40%-plus gross margin and are confident that we can return to that level as we work toward higher capacity utilization across our facilities as demand for our cannabis products continue to grow. In the meantime, we are focused on further optimizing our operating footprint through a full end-to-end strategy that looks at people, process, technology, and infrastructure that we believe will lead to best in class margins over time.”
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1737927/000156459020038957/cgc-10q_20200630.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Canopy Growth Corp.
Canopy Growth Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
Rating
Learn More![]()
Upon the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event, Canopy Growth will have the right exercisable for a period of 30 days, to acquire all of the issued and outstanding Floating Shares for cash or common shares or a combination thereof, in Canopy Growth's sole discretion at a price equal to the 30-day volume weighted average trading price of the Floating Shares on the CSE, subject to a minimum call price of US$6.41 per Floating Share.
Management calculates Adjusted EBITDA as the reported net loss, adjusted to exclude income tax recovery (expense); other income (expense), net; loss on equity method investments; share-based compensation expense; depreciation and amortization expense; asset impairment and restructuring costs; and charges related to the flow-through of inventory step-up on business combinations, and further adjusted to remove acquisition-related costs.
The increase of $10.4 million in the deferred income tax recovery is primarily a result of (i) recording a reduction in deferred tax liabilities that arose in connection with the required revaluation of the accounting carrying value, but not the tax basis, of property, plant and equipment, intangible assets, and other financial assets; and (ii) the recognition of losses carried forward net of the use of losses carried forward from prior years for which a deferred tax asset had been recorded.
The increase of $2.9 million in the current income tax recovery arose primarily in connection with legal entities that generated losses during the current period that will be used to reduce prior years' income for tax purposes, and acquired legal entities that generated income for tax purposes during prior periods that could not be reduced by the group's tax attributes but whose current period income will now be reduced by the group's tax attributes.
Immediately prior to the acquisition of the Fixed Shares, each issued and outstanding Fixed Multiple Share will automatically be exchanged for one Fixed Share and thereafter be acquired by Canopy Growth upon the same terms and conditions as the acquisition of the Fixed Shares; If the occurrence or waiver of the Triggering Event does not occur within 10 years from the date the Amended Arrangement is implemented, Canopy Growth's rights to acquire both the Fixed Shares and the Floating Shares will terminate; Upon implementation of the Amended Arrangement, Canopy Growth will make a cash payment to the shareholders of Acreage and holders of certain securities convertible into Existing SVS in the aggregate amount of US$37.5 million; and Acreage is only permitted to issue an aggregate of up to 32,700,000 Fixed Shares and Floating Shares following the implementation of the Amended Arrangement.
Pursuant to the terms of...Read more
Following the occurrence or waiver...Read more
We undertake no obligation to...Read more
A decrease in interest income...Read more
Additionally, This Works contributed a...Read more
The year-over-year decrease in the...Read more
Our "Adjusted EBITDA" is a...Read more
C (acquired in April 2019)...Read more
The following table presents Adjusted...Read more
The year-over-year increase is primarily...Read more
In the first quarter of...Read more
The year-over-year decrease is primarily...Read more
Accordingly, management believes that Adjusted...Read more
Management believes that free cash...Read more
The year-over-year increase of $13.3...Read more
Therefore, we are subject to...Read more
As a result, there is...Read more
Comparatively, in the first quarter...Read more
Given the uncertainties associated with...Read more
Partially offsetting these decreases in...Read more
The decrease in the net...Read more
A variety of factors, including...Read more
This Management's Discussion and Analysis...Read more
In connection with certain deferred...Read more
The year-over-year decrease in the...Read more
The above factors resulting in...Read more
These forward-looking statements are generally...Read more
Revenue from Storz & Bickel...Read more
Change of $41.6 million related...Read more
In the first quarter of...Read more
We established a COVID-19 Management...Read more
Free cash flow is a...Read more
Additional cash inflows during the...Read more
The total principal amount owing,...Read more
The year-over-year decrease is primarily...Read more
These factors were partially offset...Read more
We have continued to operate...Read more
Specifically, the increase in the...Read more
Comparatively, the price of our...Read more
Readers are cautioned to consider...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Canopy Growth Corp provided additional information to their SEC Filing as exhibits
Ticker: CGC
CIK: 1737927
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-20-038957
Submitted to the SEC: Mon Aug 10 2020 4:31:05 PM EST
Accepted by the SEC: Mon Aug 10 2020
Period: Tuesday, June 30, 2020
Industry: Medicinal Chemicals And Botanical Products